The Non Inflammatory Solution

GenesisCS Component Concentrating System

Pure PRP™

Platelet rich plasma point of care therapy has been perfected with Pure PRP™.  Pure PRP™ offers all of the good and none of the bad.  Pure PRP™ is a platelet rich plasma preparation that contains highly concentrated platelet growth factors with no red blood cells.  Pure PRP™ is also unique because it is the only PRP system that can be processed with or without neutrophil granulocytes.  The platelet and growth factor concentrations are 7 to 9 X baseline and the yields range from 80-98%.  The collected PRP sample is 6mL from a 60mL sample of anticoagulated whole blood.  Pure PRP™ is the absolute solution to meets all clinical demands.  With the Pure PRP™, physicians can now offer true growth factor concentrates in a medium that is suitable for active wound repair.

pumpGenesisCS Pure PRP™  Sample: 6 mL
Platelet Concentrations: 7-9 X Baseline
Platelet Yields: 80-959’0
RBC Yields: 0%
Neutrophil Granulocyte Yields: 0-1%

No Red Blood Cells (RBCs)

Pure PRP™ provide high concentrations of platelet & growth factors in a pure plasma suspension. It has a no red blood cells which increases PRP viscosity making it more difficult to inject. Red blood cells in PRP has also been reported to cause pain. With Pure PRP™ this risk is eliminated. It is the purest sample of platelet rich plasma available at the point of care.

Process with or without Neutrophil Granulocytes

The polymorphonuclear cell family (PMNs) includes the body’s most abundantly occurring granulocyte known as neutrophils [1][2][3]. These granulocytes, in abundant & sustained doses releases cytokines, which can amplify  inflammatory reactions by several other cell types [4]. This inflammation is  needed for active wound repair, but in some cases is undesirable.  Pure PRP™ is the only PRP system that can be processed with or without neutrophil granulocytes, providing physicians with their choice of active components needed for the care of their patients.

REFERENCES
  1. Witko-Sarsat,V; Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L (2000). “Neutrophils: molecules,functions and pathophysiological aspects’: Lab Invest 80 (5): 61 7-53.
    doi:l0.1038Ilabinvest.3780067.PMlD 10830774.
  2. Klebanoff, SJ; Clark, RA (1978).The Neutrophil: Function and Clinical Disorders. ElsevierlNorth-Holland Amsterdam. ISBN 0444800204.
  3. Nathan, C (Mar 2006). “Neutrophils and immunity: challenges and opportunities’: Nature Reviews Immunology 6 (March): 173-82. doi:lO.l038/nri1785. ISSN 1474-1733.PMID 16498448
  4. EarT, McDonald PP (2008). “Cytokine generation, promoter activation, and oxidant-independent NF-kappaB activation in a transfectable human neutrophilic cellular model: BMC Immunol. 9:
    doi:l0.1186/1471-2172-9-14.PMC 2322942. PMlD 18405381